Due to significant ocular toxicity affecting most patients, the approved starting dose for belantumab is likely not optimal long-term. Effective management requires clinicians to proactively hold, delay, and reduce doses at the first sign of side effects, meaning real-world application will differ from the initial protocol.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

Standard liver panels check ALT and AST, but Gamma-glutamyl transferase (GGT) is a more sensitive marker for liver stress, particularly from alcohol or certain supplements. It often elevates before other enzymes, acting as a 'canary in the coal mine' for potential liver issues.

A real-world analysis of pemigatinib reported low rates of dose reduction or discontinuation. This may be misleading, as the toxicities of FGFR inhibitors (e.g., nail, skin, eye issues) are cumulative and worsen over extended periods. The study's shorter follow-up likely didn't capture the full long-term safety profile of the drug.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

A key nuance in managing ponatinib for Ph+ ALL is a response-adapted dosing strategy. Patients are typically started at a 30mg dose, which is then reduced to 15mg once a good minimal residual disease (MRD) response is achieved. This approach aims to maintain efficacy while mitigating long-term toxicity.

Clinicians recommend starting lenvatinib at the full 20mg dose rather than escalating from a lower dose. This ensures therapeutic levels are reached. They then dose-reduce aggressively as needed. Starting low risks falsely concluding the drug is ineffective if the patient tolerates a suboptimal dose without response.

Although 60% of patients required a dose reduction for talazoparib, the expert argues for the higher starting dose. He believes it secures a more durable and long-lasting response, which is crucial, even if it necessitates later dose adjustments due to toxicity like anemia.